EcoDrugPlus

Serpin Family C Member 1

Ensembl ID : ENSRROG00000036408
Gene Symbol: SERPINC1
4 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSRROG00000003045
Gene Symbol: SIGMAR1
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sirtuin 1

Ensembl ID : ENSRROG00000034429
Gene Symbol: SIRT1
2 Cross references
157 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSRROG00000030252
Gene Symbol: SMO
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSRROG00000044856
Gene Symbol: SCNN1A
4 Cross references
153 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSRROG00000001691
Gene Symbol: SCNN1B
4 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSRROG00000033855
Gene Symbol: SCNN1G
4 Cross references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSRROG00000038441
Gene Symbol: SCN1A
4 Cross references
139 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSRROG00000002301
Gene Symbol: SCN10A
4 Cross references
297 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSRROG00000041360
Gene Symbol: SCN11A
4 Cross references
96 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSRROG00000040513
Gene Symbol: SCN2A
4 Cross references
130 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSRROG00000036013
Gene Symbol: SCN3A
2 Cross references
167 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).